375 related articles for article (PubMed ID: 30666357)
1. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.
Abu-Sbeih H; Ali FS; Qiao W; Lu Y; Patel S; Diab A; Wang Y
Cancer Immunol Immunother; 2019 Apr; 68(4):553-561. PubMed ID: 30666357
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
3. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.
Judd J; Zibelman M; Handorf E; O'Neill J; Ramamurthy C; Bentota S; Doyle J; Uzzo RG; Bauman J; Borghaei H; Plimack ER; Mehra R; Geynisman DM
Oncologist; 2017 Oct; 22(10):1232-1237. PubMed ID: 28652280
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T
Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424
[No Abstract] [Full Text] [Related]
7. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
[TBL] [Abstract][Full Text] [Related]
9. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
11. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
12. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
[TBL] [Abstract][Full Text] [Related]
14. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
15. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Freeman-Keller M; Kim Y; Cronin H; Richards A; Gibney G; Weber JS
Clin Cancer Res; 2016 Feb; 22(4):886-94. PubMed ID: 26446948
[TBL] [Abstract][Full Text] [Related]
17. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy.
Shafqat H; Gourdin T; Sion A
Semin Oncol; 2018 Jun; 45(3):156-163. PubMed ID: 30348532
[TBL] [Abstract][Full Text] [Related]
18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
19. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
20. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
Maillet D; Corbaux P; Stelmes JJ; Dalle S; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Freyer G; Boespflug A; Péron J
Eur J Cancer; 2020 Jun; 132():61-70. PubMed ID: 32334337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
